Dynavax Technologies Corporation (DVAX)

Stock Card

$15.50

$0.00 (0.00%)

As on 10-Feb-2026 16:00EDT

Market cap

$1,820 Mln

Revenue (TTM)

$331 Mln

P/E Ratio

P/B Ratio

3.3

Div. Yield

0 %

Dynavax Technologies (DVAX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: 9.20 High: 15.73

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

30.9
Debt to Equity

0.4
Book Value

$--
EPS

$-0.4
Face value

--
Shares outstanding

113,684,064

10 Years Aggregate

CFO

$-196.86 Mln

EBITDA

$-262.92 Mln

Net Profit

$-443.71 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Dynavax Technologies (DVAX)	0.8	0.6	43.1	17.9	12.1	7.9	-1.6
BSE Sensex^*	-9.4	-1.8	2.6	-3.9	5.8	5.9	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 10-Feb-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Dynavax Technologies (DVAX)	20.4	-8.6	31.4	-24.4	216.2	-22.2	-37.5
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Dynavax Technologies (DVAX)	15.5	1,820.1	330.5	-43.4	-10.3	-8.1	--	3.3
aTyr Pharma (LIFE)	36.3	3,703.2	586.5	-106.4	-16.6	--	--	5.3
Generation BioÂ Co (GBIO)	5.3	36.0	15.3	-62.6	-414.9	-101.1	--	0.7

Shareholding Pattern

View Details

About Dynavax Technologies (DVAX)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of... infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Read more

CEO, Interim CFO & Director

Mr. Ryan Spencer
CEO & Director

Mr. Ryan Spencer
Headquarters

EmeryVille, CA
Website

https://www.dynavax.com

FAQs for Dynavax Technologies (DVAX)

What is the current share price of Dynavax Technologies Corporation (DVAX) Today?

The share price of Dynavax Technologies Corporation (DVAX) is $15.50 (NASDAQ) as of 10-Feb-2026 16:00 EDT. Dynavax Technologies Corporation (DVAX) has given a return of 12.11% in the last 3 years.

What is the current PB & PE ratio of Dynavax Technologies Corporation (DVAX)?

Since, TTM earnings of Dynavax Technologies Corporation (DVAX) is negative, P/E ratio is not available.
The P/B ratio of Dynavax Technologies Corporation (DVAX) is 3.30 times as on 10-Feb-2026, a 36 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	71.55	3.27
2023	-291.63	3.00
2022	5.51	2.78
2021	22.92	7.91
2020	-6.52	8.36

What is the 52 Week High and Low of Dynavax Technologies Corporation (DVAX)?

The 52-week high and low of Dynavax Technologies Corporation (DVAX) are Rs 15.73 and Rs 9.20 as of 01-Sep-2026.

What is the market cap of Dynavax Technologies Corporation (DVAX)?

Dynavax Technologies Corporation (DVAX) has a market capitalisation of $ 1,820 Mln as on 10-Feb-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Dynavax Technologies Corporation (DVAX)?

Before investing in Dynavax Technologies Corporation (DVAX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.